The global drug & gene delivery devices market size was valued at USD 533.24 billion in 2020 and is anticipated to reach a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising research on improved drug delivery and high number of new drug delivery system.
The drug & gene delivery devices are the types of medical equipment that are primarily designed and used to operate the delivery of the drugs and genes for the treatment of the disease. The drug and gene delivery system are applied for the treatment of different disease caused from bacterial infections, malignant tumors, viral invasions, external chemical toxins, and endogenous genetic defects. Drug delivery systems are constantly improving as well as changing choices of the patient. For example, earlier hormone replacement therapy was prescribed as pills, however, it is prescribed in as vaginal rings, patches, gel, prefilled syringes, and sprays. The main purpose of preparing several types of delivery systems is to improve the ease of use. The delivery system is also developed based on the factors such as price, aesthetics of the delivery systems, and amount of API. The recent advancements in the delivery system are development of auto-injectors, development of biopharmaceutical classification systems (BCS) class II oral dosage form drugs, presence of improved implants in customized sizes & shapes, and development of advanced pulmonary devices such as adaptive aerosol delivery and smartcard.
The COVID-19 pandemic affected the whole world due to travel restrictions, nationwide lockdowns, and high cases of COVID-19 across the globe. This pandemic opened new opportunities for the drug delivery market as the research & development activities increased and key market players started investing to find new delivery systems to comfort the patients and give better results.
Market Trends, Drivers, Restraints, and Opportunities
- Growing funding by the major players to introduce innovative drug delivery systems to supply to the demand of the patients along with to improve the bioavailability at smallest quantity of active pharmaceutical ingredient are propelling the market expansion in the near future.
- Rising attention on R&D of gene delivery systems due to the huge growth potential of gene therapy for the treatment of several deadly diseases is proving to boost the market growth.
- High prevalence of chronic disease across the world and large number of the targeted patients are key factors for the market growth.
- Low interest of government from developing regions and high cost of development are key challenges that can restrain the market growth in the coming years.
- High number of diseases in the world and growing preference of improved delivery systems along with growing R&D activities across the world are key opportunities for the market during the forecast period.
Scope of the Report
The report on the global drug and gene delivery devices market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Drug & Gene Delivery Devices Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Drug Delivery Types (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, and Topical), Gene Delivery Vectors (Viral and Non-viral), and Gene Delivery Types (In Situ and Ex Vivo)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Novartis AG; Pfizer; Inc.; F. Hoffmann-La Roche Ltd; Johnson and Johnson Private Ltd; Bayer AG; and Becton, Dickinson and Company
|
Market Segment Insights
Oral segment is expected to grow at a rapid pace
Based on drug delivery types, the global drug & gene delivery devices market is divided into injectable, oral, inhalation, ocular, transdermal, nasal, and topical. The oral segment is expected to grow at a rapid pace during the projected period owing to the factors such as ease of use, easy availability, and self-administration.
The injectable segment, on the other hand, is expected to grow at significant growth rate in the coming years as the potency is high, increased investments by the biotechnological companies, improved products, and introduction of self-injection. The oral route has a disadvantage of deterioration of drugs that is overcome by the injectable route.
Viral vector segment is projected to expand at a considerable CAGR
On the basis of gene delivery vectors, the global market is bifurcated into viral and non-viral. The viral vector segment is projected to expand at a considerable CAGR during the forecast period attributed to the factors as there are 60% or above clinical trials on gene therapies currently ongoing, which are based on viral vectors for transfection. Additionally, there are four approved drugs in the market with viral vectors and the success rate of viral vector is also higher than the non-viral vector. These factors are expected to propel the market segment to new level of growth. Viral vector are also used for complex transfection procedures, which are ultrasound, gene gun, hydrodynamic, and magnetofection.
In situ segment is anticipated to grow at a substantial rate
Based on the gene delivery types, the global drug & gene delivery devices market is classified as in-situ and ex vivo. The in situ segment is anticipated to dominate the market as maximum drugs in the market are adopted with in situ methods. Furthermore, the segment growth is further accelerated due to the ease of use and high preference of healthcare professionals along with the low efficiency of transduction process by this method.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the projected period as the region has high number of major players and witnessed high funding in development of novel drug delivery systems. Moreover, high approval rate of the drugs in the region as well as favorable government policies especially in the US in the R&D programs are pushing the market growth in the region.
Meanwhile, the market of Asia Pacific is projected to exhibit significant growth during the forecast period. The regional market growth is attributed to high disease prevalence, increasing awareness about delivery systems, and international investments in the region by the major market players. The region is anticipated to witness huge growth opportunities for growth and development of novel delivery systems.
Segments
Segments Covered in the Report
The global drug & gene delivery devices market has been segmented on the basis of
Drug Delivery Types
- Oral
- Inhalation
- Transdermal
- Injectable
- Ocular
- Nasal
- Topical
Gene Delivery Vectors
Gene Delivery Types
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Novartis AG
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Johnson and Johnson Private Ltd
- Bayer AG
- Becton, Dickinson and Company
Competitive Landscape
Key players competing in the drug & gene delivery devices market are Novartis AG; Pfizer; Inc.; F. Hoffmann-La Roche Ltd; Johnson and Johnson Private Ltd; Bayer AG; and Becton, Dickinson and Company.
Request For Customization
Enquiry Before Buying
Speak With Analyst
